Display options
Cite
Careri JM, Draine AE, Hanover R, et al. A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. Prim Care Companion CNS Disord. 2015;17(6)doi: 10.4088/PCC.15m01831.
Careri, J. M., Draine, A. E., Hanover, R., & Liebowitz, M. R. (2015). A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. The primary care companion for CNS disorders, 17(6), . https://doi.org/10.4088/PCC.15m01831
Careri, Jason M, et al. "A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder." The primary care companion for CNS disorders vol. 17,6 (2015). doi: https://doi.org/10.4088/PCC.15m01831
Careri JM, Draine AE, Hanover R, Liebowitz MR. A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. Prim Care Companion CNS Disord. 2015 Nov 26;17(6). doi: 10.4088/PCC.15m01831. eCollection 2015. PMID: 27057414; PMCID: PMC4805415.
Copy Download .nbib Format: NLM
Share it on

Prim Care Companion CNS Disord. 2015 Nov 26;17(6). doi: 10.4088/PCC.15m01831. eCollection 2015.

A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder.

The primary care companion for CNS disorders

Jason M Careri, Ann E Draine, Rita Hanover, Michael R Liebowitz

Affiliations

  1. The Medical Research Network, LLC, New York, New York.
  2. Westport Compass, Salt Lake City, Utah.

PMID: 27057414 PMCID: PMC4805415 DOI: 10.4088/PCC.15m01831

Abstract

OBJECTIVE: To examine the efficacy, safety, and tolerability of vilazodone for subjects (aged 18-75 years) with generalized social anxiety disorder.

METHOD: Forty-four subjects with generalized social anxiety disorder (DSM-IV-TR criteria) were randomized to vilazodone or placebo in a 12-week double-blind, flexible-dose trial. Change from baseline to endpoint on the Liebowitz Social Anxiety Scale (LSAS) was the primary outcome measure. Secondary outcome measures included response and remission rates and changes in depression and anxiety. Data were collected between November 2012 and April 2014. The study was conducted at a private clinical trials facility in New York, New York.

RESULTS: The mean baseline LSAS score was 91.9 (SD = 17.5) and the mean Clinical Global Impressions-Severity scale score was 5.3 (SD = 0.56), indicating marked to severe illness. There were no significant baseline differences in severity of social anxiety between the treatment groups. At the end of treatment, in the intent-to-treat sample (n = 39), the vilazodone group had improved significantly more than the placebo group by 14.3 points on the LSAS (t = 1.80, P = .04, one-tail test) (Cohen d = 0.58).

CONCLUSIONS: The findings suggest that vilazodone may be a promising treatment for social anxiety disorder. Further study is needed given the limited sample size.

TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01712321.

References

  1. Mod Probl Pharmacopsychiatry. 1987;22:141-73 - PubMed
  2. Psychol Med. 2008 Jan;38(1):15-28 - PubMed
  3. Depress Anxiety. 2015 Jun;32(6):451-9 - PubMed
  4. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57 - PubMed
  5. Br J Med Psychol. 1959;32(1):50-5 - PubMed
  6. Pain Res Treat. 2012;2012:621619 - PubMed
  7. JAMA. 1998 Aug 26;280(8):708-13 - PubMed
  8. J Clin Psychiatry. 2009 Mar;70(3):326-33 - PubMed
  9. J Clin Psychopharmacol. 2011 Oct;31(5):643-6 - PubMed
  10. Am J Psychiatry. 2001 Feb;158(2):275-81 - PubMed
  11. J Clin Psychiatry. 2005 Feb;66(2):238-47 - PubMed
  12. J Clin Psychopharmacol. 2004 Apr;24(2):118-25 - PubMed
  13. J Clin Psychiatry. 2011 Apr;72(4):441-7 - PubMed
  14. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62 - PubMed
  15. Psychol Med. 2010 Jun;40(6):977-88 - PubMed
  16. Psychol Med. 1999 Jan;29(1):199-212 - PubMed

Publication Types